Eliane Meurs, et al.. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.: CD81 and HCV infection of primary hepatocyte. Abstract :98 words ; text : 1600 words 9 ABSTRACT 1 HCV-positive serum (HCVser, genotypes 1a-3a) or JFH1/HCVcc infection of primary normal 2 human hepatocytes was assessed by measuring intracellular HCV RNA strands. Anti-CD81
Anti-CD81 monoclonal antibodies (mAbs) JS81 and JS64 inhibited HCVser 1 (genotypes 1-3) infection of hepatocytes in a concentration-dependent manner (Figure 1A -2 C). On average, mAbsJS81 produced 92±9% inhibition. Anti-CD9 mAbsM-L13 or mouse 3 IgG1 isotype control produced no inhibition. When cells were treated with mAbsJS81 at the 4 time of inoculation (T0) or shortly after (30 min), the accumulation of both negative and 5 positive HCV RNA strands was clearly reduced (>90% on positive strand) (Figure 1D-E) . 6
However, as the interval between HCVser inoculation and anti-CD81 treatment increased, the 7 inhibitory effect gradually decreased. When antibodies were added 8 hours after inoculation, 8 the inhibition was markedly reduced. Neither anti-CD81 nor anti-CD9 mAbs prevented the 9 HDV infection of hepatocytes (not shown). The inhibitory effect of anti-CD81 mAbs is 10 therefore interfering with an early step of HCVser cell entry, and specific to HCV infection. 11
To reduce CD81 expression, hepatocytes were transduced with FG12 lentivirus (33) 12 expressing siRNAs directed against hCD81 mRNA, CD81/siRNA412 (5'-13 GCAGTTCTATGACCAGGCC-3'), CD81/siRNA619 3') or CD81/siRNA1262 . Cells transduced with 15 lentivirus expressing human Constitutive Androstane Receptor (CAR) siRNA (5'-16 GCATGAGGAAAGACATGA, CAR/siRNAc382) (45) or GFP only were used as controls . 17 More than 90% of cells were transduced as assessed by GFP expression and western blot 18 analysis revealed that CD81 siRNA produced a >75% inhibition of CD81 expression (not 19 shown). Levels of membrane-bound CD81 assessed by FACS analysis were strongly 20 decreased in CD81 siRNA-transduced cells as compared to CAR siRNA-or FG12-transduced 21 cells (Figure 1F) . hCD81 siRNAs produced a consistent and significant inhibition (91±6% at 22 MOI 1, p<0.01) of HCVser genome replication, while CAR siRNA or empty lentivirus did 23 not (Figure 1F) . These results confirm the role of CD81 in the HCVser infection of human 24 hepatocytes. 25
Recombinant CD81-LEL GST-fusion proteins from man, african green monkey and 1 mouse were synthesized as described (17) . We first verified that hCD81-LEL binds 2 glycoprotein E2 and that LEL and anti-CD81 mAbs JS81 and JS64 markedly inhibit (>90%) 3 JFH1/HCVcc infection of Huh-7.5 cells (not shown), as observed by others (23, 43) . 4
Interestingly, hCD81-LEL did not inhibit HCVser infection of hepatocytes (Figure 2A-B) . As 5 this was rather unexpected, we compared HCVser and JFH1/HCVcc infection of human 6 hepatocytes. We first established that under our standard conditions of infection (9, 15, 26) , 7 JFH1/HCVcc infect hepatocytes at Geq/cell ratio 0.03 and 0.1, as assessed by both genomic 8 and replicative HCVcc RNA strand accumulation in cells and production of infectious virions 9 in cell supernatant (not shown). JFH1/HCVcc genomic strand level was 3.3±1 (n=3; range: 10 2.5-4.1) copies per hepatocyte after infection at Geq/cell ratio 0.03 (and 9.7 at Geq/cell ratio 11 0.1). This is an order of magnitude greater than that observed (0.18±0.10) after HCVser 12 infection at the same Geq/cell ratio. Unexpectedly, however, JFH1/HCVcc infection of 13 human hepatocytes was inhibited significantly but only partly (40-60%) by both hCD81-LEL 14 and in HCVser infection of hepatocytes (Figure 1, 92% ). 17
The current observation that hCD81-LEL does not inhibit HCVser infection of 18 hepatocytes, and only partly inhibits JFH1/HCVcc infection of hepatocytes is puzzling on the 19 basis that HCVser does infect human hepatocyte in a CD81-dependent manner that can be 20 specifically inhibited with anti-CD81 mAbs or CD81 specific siRNA. Indeed, previous (and 21 current) studies have shown that hCD81-LEL strongly reduces HCVpp or JFH1/HVCcc 22 infection of 7, 10, 18, 23, 43, 46) . Several hypothesis may be 23 proposed for this observation. First, it is possible that within the infectious HCVser 24 lipoviroparticles (2, 19, 25, 41) , lipoproteins prevent the interaction between glycoprotein E2 25 and hCD81-LEL. This is supported by the findings that viral particles from human plasma do 1 not bind hCD81-LEL (44) and that some human sera have to be treated with a detergent 2 (deoxycholate) to release HCV particles able to interact with CD81 in Huh-7 cells (40). 3 Second, it is possible that the affinity of hCD81-LEL for E2 is much lower than that of 4 membrane-bound CD81 in normal hepatocyte. Third, a primary binding of HCVser to a non-5 CD81 membrane molecule as for example 26) , may trigger the virus 6 binding to CD81 on the hepatocyte membrane so that hCD81-LEL cannot compete in the 7 natural membrane environment. 8
In contrast to recombinant CD81-LEL proteins which are expected to compete with 9 the natural membrane receptor for binding virus particles, antibodies directly target the 10 cellular receptor. Their efficiency is therefore expected to be greater. This is consistent with 11 current results revealing that the efficacy of mAbJS81 is approximately one to two orders of 12 magnitude greater than that of recombinant hCD81-LEL, on a molar concentration basis (not 13 shown). Anti-CD81 mAbs inhibited JFH1/HCVcc infection of primary hepatocytes to a 14 weaker extent (60%) as compared with HCVser infection of primary hepatocytes (92%), and 15 JFH1/HCVcc infection of Huh-7.5 cells (>90%, not shown). It is possible that the higher 16 input of infectious virus in JFH1/HCVcc versus HCVser infection of hepatocytes, the 17 difference in affinity or kinetics of HCV interaction with Huh-7.5 versus hepatocyte 18 membrane receptors, and the difference in membrane protein population in Huh-7.5 cells 19 versus hepatocytes account for these differences in inhibition efficiency. In sum, the data 20 obtained on recombinant CD81-LEL and anti-CD81 antibodies suggest that CD81 has a much 21 greater impact on the entry of JFH1/HCVcc in Huh-7.5 cells than it does on the entry of 22
HCVcc particles in primary hepatocytes. Nevertheless, other data provided here show that 23 CD81 indeed mediates the entry of HCVser in hepatocytes. It is therefore possible that the 24 It is interesting that JFH1/HCVcc particles are able to infect primary human 1 hepatocytes as revealed here by the intracellular accumulation of both genomic and 2 replicative (not shown) strands. Indeed, although HCVser are infectious for primary 3 hepatocytes, it has to be noted that less than 15% of the tested sera are actually infectious 4 (15). The reason for this observation is unclear but could be related to the presence of anti-5 HCV antibodies in the serum of chronically infected patients. In addition, the Geq/cell ratio 6 with HCVser can hardly be greater than 0.1 because of the limited amounts of infectious 7 serum. Hence, the possibility to infect primary hepatocytes with unlimited amounts of 8 JFH1/HCVcc at much greater Geq/cell ratio will strongly facilitate future studies. The rate of 9 genome replication of JFH1/HCVcc in human hepatocytes appears to be one order of 10 magnitude greater than that observed with HCVser, whereas it is one order of magnitude 11 smaller than that observed in Huh-7.5 cells at the same Geq/cell ratio. Thus, although 12 JFH1/HCVcc particles are adapted to Huh-7.5 cells, they can replicate their genome and 13 proliferate in primary human hepatocytes, albeit at a lower rate. This could result from the 14 greater antiviral response of human hepatocytes as compared to Huh-7.5 cells (L. Pichard-15 Garcia, S. Molina, P. Maurel, unpublished results). On the other hand, the fact that the rate of 16 genome replication of JFH1/HCVcc in hepatocytes is greater than that of HCVser suggests 17 that either only a small portion of HCVser virions are infectious, or antibodies present in the 18 serum strongly affect their infectivity. 19
In conclusion, CD81 plays a critical role in an early step of HCVser infection of 20 primary human hepatocytes. Comparative studies on HCVser versus JFH1/HCVcc infection 21 of human hepatocytes and on JFH1/HCVcc infection of human hepatocytes versus Huh-7.5 22 cells suggest that the nature of the couple cell-virion is a determinant factor for virus entry. 23
This would be consistent with the fact that several receptor candidates have been identified for HCV and that their interactions with one another or with other membrane components 1 might modulate the way they associate with the various virion populations. , J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F.  7 Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C 8 virus infection in vitro. Proc Natl Acad Sci U S A 102:9294-9. 9 10 11 LEGENDS 1
FIGURE 1. Effect of anti-CD81 mAbs and of siRNA-mediated silencing of CD81 on 2

HCVser infection of primary human hepatocyte (PHH) 3
Three days post-plating, hepatocytes FTBP from a 52y-old male with metastasis of colic 4 tumor were exposed or not (UT) to increasing concentrations (0.5 to 6 µg/ml) of anti-CD81 5 mAbs JS81 or JS64, or anti-CD9 mAbs M-L13, or mouse IgG1 isotype MOPC-21 for 30 min 6 before inoculation with HCV(+) serum S298 (genotype 3a, 1.5 10 6 IU/mL). Following 7 overnight exposure, cells were washed three times and the culture was continued. Five days 8 post-inoculation, cells were washed three times and total cellular RNA was extracted. 9
A. One µg of total RNA was analysed by rTth-RT-PCR for the replicative RNA strand. 10 B. One µg of the same RNA sample was analysed by real-time PCR for the genomic strand. 11
RNA quality control was evaluated by performing a quantification of GAPDH mRNA in each 12 sample. Amounts of HCV RNA were normalized to GAPDH mRNA. Results are expressed 13 as percent of intracellular viral RNA relative to the amount obtained in in vitro infected 14 hepatocytes in the absence of treatment (0). Data are mean of three independent assays. These 15 results are representative of observations made with all other hepatocyte cultures from 16 different donors used in this work. 17 C. Three days post-plating, hepatocytes FT168 (75y-old female with metastasis of colic 18 tumor) were exposed to HCV(+) serum S42 (genotype 1b, 6 10 6 IU/mL), S31 (genotype 2, 13 19 10 6 IU/mL) or S34 (genotype 1b, 60 10 6 IU/mL), hepatocytes FT196 (35y-old female with 20 metastasis of colic tumor) were exposed to serum S155 (genotype 1a, 1.1 10 6 IU/mL), 21 hepatocytes FT 212 (52y-old male with metastasis of colic tumor) were exposed to serum 22 S183 (genotype 3a, 2.6 10 6 IU/mL), and hepatocytes FT249 (52y-old male with metastasis of 23 colic tumor) were exposed to serum S192 (genotype 3a, 2.5 10 6 IU/mL), in the absence (UT) 24 or presence of anti-CD81 mAbs JS81 at 4 µg/ml (mAbs), and further analysis was carried out as indicated above. Amounts of HCV RNA were normalized to GAPDH mRNA. Results are 1 expressed as percent of intracellular viral RNA relative to the amount obtained in in vitro 2 infected hepatocytes in the absence of treatment (UT). Data are mean of three independent 3 assays. These results are representative of observations made with other hepatocytes cultures 4 from different donors FT161 (35y-old male organ donor), 167 (57y-old male with metastasis 5 of colic tumor), 176 (69y-old female with metastasis of colic tumor), 195 (17y-old male organ 6 donor) and FTBP. 7 D and E. Three days post-plating, hepatocytes (FT196) were exposed to HCV(+) human 8 serum S155. Cells were left untreated (UT) or treated with anti-CD81 mAbs JS81 (4 µg/ml) 9 added either at the time of inoculation with HCV (+) serum (0), or 30 min, 1h, 2h, 4h, 8h 10 later, and further analysis was carried out as indicated above. 11 D. One µg of total RNA was analysed by rTth-RT-PCR for the replicative RNA strand. 12 E. One µg of the same RNA sample was analysed by real-time PCR for the genomic strand. three days post-plating, hepatocytes FT257 (30y-old female with hydatid cyst) or FT259 were 13 inoculated with these mixtures under our standard conditions. After exposure, cells were 14 washed three times to remove excess of inoculum and the culture was continued for 3 days. 15
Total cellular RNA was extracted and one µg was analysed by rTth-RT-PCR for the 16 replicative RNA strand (FT257/S297) or by real-time PCR for the genomic strand. Amounts 17 of HCV RNA were normalized to GAPDH mRNA. All experiments were carried out in 18 duplicate. These results represent average data obtained from these four series of experiments 19 (FT257/S297 or S298; and FT259/S297 or S298). These experiments were repeated with two 20 different lots of CD81-LEL fusion proteins with same results. 21 C and D. JFH1/HCVcc was pre-incubated or not (UT) with 10, 20 or 40 µg/ml of green 22 monkey (G), human (H), or mouse (M, only 40 µg/ml) CD81-LEL during 30 min and used to 23 inoculate hepatocytes FT273 (64y-old male with metastasis of colic tumor), FT276 (62y-old 24 female with metastasis of colic tumor) and FT281 (56y-old male with metastasis of colic tumor) at different genome equivalent per cell ratios (0.03 and 0.1), three days post-plating. 1 Three days later, cells were washed three times and total cellular RNA was extracted. One µg 2 of the same RNA sample was analysed by real-time PCR for the genomic strand. RNA quality 3 control was evaluated by performing a quantification of GAPDH mRNA in each sample. 4
Amounts of HCV RNA were normalized to GAPDH mRNA. Results are expressed as 5 genome equivalent copies per cell. Data are mean of three independent assays. Statistical 6 analysis and p values were obtained using the Wilcoxon signed-rank test. Human hepatocytes (FT273, FT276 and FT281) were inoculated with JFH1/HCVcc at 11 different genome equivalent per cell ratios (0.03 and 0.1) in the absence (UT) or presence of 12 0.5 to 6 µg/ml of anti-CD81 mAbs JS81, or JS64 added for 30 min before inoculation. 13
Control experiments were performed under the same conditions with anti-CD9 mAbs M-L13 14 (not shown). Following overnight exposure, cells were washed three times and the culture 15 was continued. Three days later, cells were washed three times and total cellular RNA was 16 extracted. One µg of total RNA was analysed by real-time PCR for the genomic strand. RNA 17 quality control was evaluated by performing a quantification of GAPDH mRNA in each 18 sample. Amounts of HCV RNA were normalized to GAPDH mRNA. Results are expressed 19 as percent of control (UT). Data are mean ± SD of three independent assays. Statistical 20 analysis and p values were obtained using the Wilcoxon signed-rank test. 
